An Ozempic injection pen is seen on a kitchen desk in Riga, Latvia, on Aug. 6, 2023.
Jaap Arriens | Nurphoto | Getty Images
Novo Nordisk on Friday raised its outlook for its full-year gross sales and working revenue as a consequence of soaring demand for its blockbuster weight reduction drug Wegovy and diabetes remedy Ozempic.
The revised forecast solely confirms the frenzy for these weekly injections, which sufferers search for their skill to assist them lose vital weight over time. Ozempic and Wegovy have propelled Novo Nordisk to grow to be Europe’s most valuable firm.
The Danish drugmaker now expects 2023 gross sales progress in native currencies of 32% to 38%, from a earlier outlook of 27% to 33%, based on a press launch.
Novo Nordisk additionally expects working revenue progress of 40% to 46%, from 31% to 37% beforehand.
The new gross sales outlook for this yr primarily displays greater expectations for Ozempic gross sales within the U.S. and “gross-to-net gross sales changes for Ozempic and Wegovy within the U.S.,” based on the discharge.
Novo Nordisk is slated to report third-quarter earnings Nov. 2.
The firm’s U.S.-listed shares rose about 1% and touched a brand new 52-week excessive Friday.